BioSpace News Archive

Asher Biotherapeutics today announced that it will present two abstracts at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), being held in Washington D.C. and virtually, November 10-14, 2021.

Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of Jeff Cambra as Chief Executive Officer.

Citius Pharmaceuticals, Inc. announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University, Philadelphia, PA, which renamed the main building housing the College of Liberal Arts to Leonard and Helena Mazur Hall in recognition of the Mazur’s longstanding commitment to Temple University’s students and alumni.

Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies for time-resolved flow cytometry. The official patent registration number is JP 6941053 B2, issued on September 7, 2021.

Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced it has started dosing of the second cohort in the Phase I TENDU trial, evaluating the Company’s Tetanus-Epitope Targeting -platform.

Nabriva Therapeutics plc announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.

NSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMR Systems to Advance Protein Structure and Dynamics Research

Compass Therapeutics, Inc. and ABL Bio, Inc. announced today that the Phase 1 monotherapy dose escalation and expansion study data for CTX-009 (ABL001/ES104), a bispecific dual angiogenesis inhibitor targeting DLL4 and VEGF-A, has been selected for an oral plenary presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held virtually on October 7-10, 2021.

AnPac Bio-Medical Science Co., Ltd. announced today its unaudited financial results for the six months ended June 30, 2021.

Latch Bio today announced the closing of a $5 million seed funding round led by Lux Capital with participation from General Catalyst, Haystack, Fifty Years, and Asimov co-founder and CEO, Alec Nielsen, Ph.D.